Diagnostic potential of a novel immunohistochemical marker, GFPT2 , in differentiating mesothelioma from its morphological mimics
Histopathology · 2026-04 · 88 (5) · 1016-1026
DOI: 10.1111/his.70062 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, online erschienen am 15.12.2025. Verfasst von Jia Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Mesothelioma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Aims
Mesothelioma (MESO) is a rare and aggressive tumour originating from mesothelial cells, primarily affecting the pleura and peritoneum. Its diagnosis remains challenging due to non‐specific clinical, radiological and histopathological features, compounded by morphological diversity and overlapping immunohistochemical profiles with other tumours. Building on our previous finding that GFPT2 is highly expressed in MESO tissues, we evaluated its diagnostic utility in distinguishing MESO from histological mimics. Methods and results We conducted an immunohistochemical analysis of GFPT2 in 101 MESO cases and 266 histological mimics, including 100 non‐small cell lung cancer (NSCLC), 40 high‐grade serous ovarian cancer (HGSOC), 6 epithelioid hemangioendothelioma (EHE), 33 solitary fibrous tumour (SFT), 23 aggressive fibromatosis (AF), 6 synovial sarcoma (SS), 7 dedifferentiated liposarcoma (DDLPS), 6 leiomyosarcoma (LMS), 4 malignant peripheral nerve sheath tumour (MPNST), 8 sarcomatoid carcinoma, 20 reactive mesothelial hyperplasia (RMH) and 13 well‐differentiated papillary mesothelial tumour (WDPMT) cases. GFPT2 positivity was detected in 85.15% (86/101) of MESO cases, significantly higher than in RMH (0%, 0/20), WDPMT (0%, 0/13), NSCLC (0%, 0/100), HGSOC (0%, 0/40), EHE (16.7%, 1/6), SFT (0%, 0/33), AF (21.74%, 5/23), SS (0%, 0/6), LMS (0%, 0/6), MPNST (25%, 1/4) and sarcomatoid carcinoma (12.5%, 1/8). However, DDLPS (85.7%, 6/7) showed high GFPT2 positivity.
Conclusions
This study demonstrates GFPT2's diagnostic utility in MESO, effectively overcoming tumour heterogeneity challenges. It distinguishes malignant mesothelial lesions from benign/borderline ones (RMH/WDPMT), differentiates epithelioid MESO from epithelioid malignances(NSCLC/HGSOC/EHE) and aids in sarcomatoid MESO versus spindle cell tumours (SFT/AF/SS/LMS/MPNST/sarcomatoid carcinoma), though limited for DDLPS. In summary, GFPT2 is a promising novel antibody demonstrating 85.2% sensitivity and 94.7% specificity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Pathology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China.
ORCID-Profile: Jia Wei, Xiaofang Ma, Gang Chen, Yan Wang, Qinhe Fan, Qixing Gong
Zitieren
APA
Wei, J., Ma, X., Chen, G., Wang, Y., Fan, Q., & Gong, Q. (2026). Diagnostic potential of a novel immunohistochemical marker, GFPT2 , in differentiating mesothelioma from its morphological mimics. Histopathology, 88(5), 1016-1026. https://doi.org/10.1111/his.70062
Vancouver
Wei J, Ma X, Chen G, Wang Y, Fan Q, Gong Q. Diagnostic potential of a novel immunohistochemical marker, GFPT2 , in differentiating mesothelioma from its morphological mimics. Histopathology. 2026;88(5):1016-1026. doi:10.1111/his.70062
BibTeX
@article{Wei2026,
author = {Wei, Jia and Ma, Xiaofang and Chen, Gang and Wang, Yan and Fan, Qinhe and Gong, Qixing},
title = {Diagnostic potential of a novel immunohistochemical marker, GFPT2 , in differentiating mesothelioma from its morphological mimics},
journal = {Histopathology},
year = {2026},
volume = {88},
number = {5},
pages = {1016--1026},
doi = {10.1111/his.70062}
}
EUVIMED